J&J's Erleada Approved By FDA In New Prostate Cancer Indication

 
• By Jessica Merrill

Erleada was approved for treatment of metastatic castration-sensitive prostate cancer (mCSPC), strengthening its position versus generic Zytiga and Pfizer/Astellas's Xtandi.

Prostate-cancer
Erleada was approved by FDA for metastatic castration-sensitive prostate cancer

More from Anticancer

More from Therapy Areas